Mersana Therapeutics Aktie

Day One Biopharmaceuticals has completed the acquisition of Mersana Therapeutics for $25 per share in cash; additionally there is a non‑tradable contingent value right (CVR) with potential payments of up to $30.25 per share. Approximately 60.6% of outstanding Mersana shares were tendered; Mersana is now a wholly owned subsidiary and trading of the shares has been halted on Nasdaq. The acquisition expands Day One’s clinical pipeline with Emi‑Le (Emiltatug Ledadotin) for the treatment of adenoid cystic carcinoma; the maximum total consideration, if milestones are achieved, can amount to $55.25 per share. » More on de.investing.com

Day One Biopharmaceuticals has announced a cash offer of $25.00 per share for Mersana Therapeutics; this represents a large premium to the previous day's price. In addition, Contingent Value Rights could pay out up to $30.25 per share if clinical, regulatory and commercial milestones are achieved for the ADC Emi‑Le. The transaction could total around $285 million, and Mersana would become a wholly owned subsidiary of Day One; the deal is expected to close by the end of January 2026 and is subject to customary conditions. » More on de.investing.com

Mersana Therapeutics reported a loss per share of $4.87 for the quarter ended June 30, 2025, compared with a loss of $5.00 in the year-ago quarter. Revenue rose to $3.1 million, an increase of 33.62% from $2.3 million a year earlier. » More on finanzen.net